4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma	Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Gaucher disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, epithelial neoplasm, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor, sphingolipidosis	Not yet recruiting	Phase 1 / Phase 2	2026-09-01		NCT04637503

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Shenzhen Geno-Immune Medical Institute	43

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Shenzhen Geno-Immune Medical Institute	Shenzhen	China	1